


Listing of Claims:

Claims 1-53 (cancelled).

Claim 54 (previously amended) A method of treating a subject suffering from a disorder selected from the group consisting of hypersensitivity, allergy, asthma and bronchospasm, which method comprises administering to the subject a therapeutically effective dose of a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of Formula I or Formula II,

wherein Formula I is as follows:



Formula I

or a pharmaceutically acceptable salt thereof, wherein

- (a) R₁, R₂, R₃, R₄ and R₅ are independently selected from the group consisting of H, OH, halogen, cyano, NO₂, alkyl, C₁₋₈ alkoxy, C₁₋₈ alkylsulfonyl, C₁₋₄ carboalkoxy, C₁₋₈ alkylthio, difluoromethoxy, difluoromethylthio, trifluoromethyl, and oxadiazole (formed by R₁ and R₂);
- (b) R₆ is selected from the group consisting of H, C₁₋₅ straight or branched alkyl, aryl, 3-piperidyl, N-substituted 3-piperidyl, N-substituted 2-pyrrolidinyl methylene, and substituted alkyl, wherein


said N-substituted 3-piperidyl and said N-substituted 2-pyrrolidinyl methylene may be substituted with C₁₋₈ straight or branched chain alkyl or benzyl, and said substituted alkyl may be substituted with C₁₋₈ alkoxy, C₂₋₈ alkanoyloxy, phenylacetyloxy, benzoyloxy, hydroxy, halogen, p-tosyloxy, mesyloxy, amino, carboalkoxy or NR'R'', wherein

(i) R' and R'' are independently selected from the group consisting of H, C₁₋₈ straight or branched alkyl, C₃₋₇ cycloalkyl, phenyl, benzyl, and phenethyl, or (ii) R' and R'' together form a heterocyclic ring selected from the group consisting of piperidino, pyrrolidino, morpholino, thiomorpholino, piperazino, 2-thieno, 3-thieno, and an N-substituted derivative of said heterocyclic rings, said N-substituted derivative being substituted with H, C₁₋₈ straight or branched alkyl, benzyl, benzhydryl, phenyl and/or substituted phenyl (substituted with NO₂, halogen, C₁₋₈ straight or branched chain alkyl, C₁₋₈ alkoxy and/or trifluoromethyl);

- (c) R₇ is selected from the group consisting of H, amino, alkyl, aryl, trifluoromethyl, alkoxymethyl, 2-thieno and 3-thieno;
- (d) R₈ is connected to the bis-sulfone ring via a single or double bond, as applicable, and is selected from the group consisting of H, alkylhydroxy, alkenyl, amino, phenyl, benzyl, C₁₋₈ straight or branched alkyl, trifluoromethyl, alkoxymethyl, C₃₋₇ cycloalkyl, substituted benzyl, formyl, acetyl, t-butyloxy carbonyl, propionyl, substituted alkyl and R'''CH₂C=O, wherein (i) said substituted benzyl is substituted with halogen, trifluoromethyl, C₁₋₈ straight and/or branched alkyl or C₁₋₈ alkoxy, (ii) said substituted alkyl is substituted with amino, dialkyl amino, C₁₋₈ alkoxy, hydroxy and/or halogen, and (iii) R''' is amino, dialkyl amino, C₁₋₈ alkoxy, hydroxy or halogen; and

- (e) m, n, and their sum are each an integer from 0 to 4;

and wherein Formula II is as follows:



Formula II

or a pharmaceutically acceptable salt thereof, wherein

- (a) R₁, R₂, R₃, R₄ and R₅ are independently selected from the group consisting of H, OH, halogen, cyano, NO₂, alkyl, C₁₋₈ alkoxy, C₁₋₈ alkylsulfonyl, C₁₋₄ carboalkoxy, C₁₋₈ alkylthio, difluoromethoxy, difluoromethylthio, trifluoromethyl, and oxadiazole (formed by R₁ and R₂);
- (b) R₇ is selected from the group consisting of H, amino, alkyl, aryl, trifluoromethyl, alkoxymethyl, 2-thieno and 3-thieno;
- (c) R₈ is connected to the bis-sulfone ring via a single or double bond and is selected from the group consisting of H, alkylhydroxy, alkenyl, amino, phenyl, benzyl, C₁₋₈ straight or branched alkyl, trifluoromethyl, alkoxymethyl, C₃₋₇ cycloalkyl, substituted benzyl, formyl, acetyl, t-butyl, alkoxy carbonyl, propionyl, substituted alkyl and R'''CH₂C=O, wherein (i) said substituted benzyl is substituted with halogen, trifluoromethyl, C₁₋₈

straight and/or branched alkyl or C₁₋₈ alkoxy, (ii) said substituted alkyl is substituted with amino, dialkyl amino, C₁₋₈ alkoxy, hydroxy and/or halogen, and (iii) R''' is amino, dialkyl amino, C₁₋₈ alkoxy, hydroxy or halogen;

- (d) R₉ is selected from -alkyl-OH, alkylamine, lactone, cyclic carbonate, alkyl-substituted cyclic carbonate, aryl-substituted cyclic carbonate, -aryl-C(O)OR', -alkyl-aryl-C(O)OR', -alkyl-OC(O)R', -alkyl-C(O)R', -alkyl-C(O)OR', -alkyl-N(R'')C(O)R', and -alkyl-N(R'')C(O)OR', wherein

R' and R'' are independently selected from the group consisting of hydrogen, amino, alkyl, aryl, aryl-fused cycloalkyl, and heterocyclyl, the amino, alkyl, aryl, aryl-fused cycloalkyl, and heterocyclyl being optionally substituted with halogen, cyano, NO₂, lactone, amino, alkylamino, aryl-substituted alkylamino, amide, carbamate, carbamoyl, cyclic carbonate, alkyl, halogen-substituted alkyl, arylalkyl, alkoxy, heterocyclyl and/or aryl (the aryl being optionally substituted with OH, halogen, cyano, NO₂, alkyl, amino, dimethylamino, alkoxy, alkylsulfonyl, C₁₋₄ carboalkoxy, alkylthio and/or trifluoromethyl);

- (e) m, n, and their sum are each an integer from 0 to 4; and
- (f) p is an integer from 0 to 4.

Claims 55-56 (cancelled).

Claim 57 (previously amended) The method of claim 54, wherein the disorder is asthma.

Claims 58-63 (cancelled).